Previous PET studies on AD and mild cognitive impairment (MCI) using the 5HT1A agent, [18F]MPPF, suggest a decrease of 5HT1A receptor availability in the hippocampus of mild cognitive impairment (MCI) patients and a greater decrease in AD patients [13]. This evidence concerns the gene HTR1A and Cognitive impairment.